达巴万星盐酸盐
达巴万星盐酸盐 性质
| 储存条件 | under inert gas (nitrogen or Argon) at 2-8°C |
|---|---|
| 溶解度 | 二甲基亚砜：≥24mg/mL（12.95 mM） |
| 形态 | 固体 |
| 颜色 | 白色至浅黄色 |
| 水溶解性 | Water: 50 mg/mL (26.98 mM) |
达巴万星盐酸盐 用途与合成方法
Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci , organisms against which it has shown greater potency than existing glycopeptide therapeutic agents.
Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens.
| Animal Model: | Female BALB/c mice (6-8 weeks) challenged with Ames strain of B. anthracis |
| Dosage: | 15 mg/kg, 30 mg/kg, 60 mg/kg, 120 mg/kg, 240 mg/kg |
| Administration: | Intraperitoneal injection; every 36 h or 72 h; for 14 days |
| Result: | The efficacy was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg/kg every 36 h or 30 to 240 mg/kg every 72 h. |
